BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hull A, Li Y, Bartholomeusz D, Hsieh W, Allen B, Bezak E. Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma: A Review of the Current Status of Literature. Cancers (Basel) 2020;12:E481. [PMID: 32092952 DOI: 10.3390/cancers12020481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Moroz A, Wang YH, Sharib JM, Wei J, Zhao N, Huang Y, Chen Z, Martinko AJ, Zhuo J, Lim SA, Zhang LH, Seo Y, Carlin S, Leung KK, Collisson EA, Kirkwood KS, Wells JA, Evans MJ. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer. Clin Cancer Res 2020;26:3608-15. [PMID: 32341034 DOI: 10.1158/1078-0432.CCR-20-0268] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
2 Koosha F, Eynali S, Eyvazzadeh N, Kamalabadi MA. The effect of iodine-131 beta-particles in combination with A-966492 and Topotecan on radio-sensitization of glioblastoma: An in-vitro study. Appl Radiat Isot 2021;177:109904. [PMID: 34454340 DOI: 10.1016/j.apradiso.2021.109904] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mashayekhi V, Mocellin O, Fens MHAM, Krijger GC, Brosens LAA, Oliveira S. Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma. Theranostics 2021;11:9022-37. [PMID: 34522225 DOI: 10.7150/thno.60350] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Li Y, Marcu LG, Hull A, Bezak E. Radioimmunotherapy of glioblastoma multiforme - Current status and future prospects. Crit Rev Oncol Hematol 2021;163:103395. [PMID: 34119657 DOI: 10.1016/j.critrevonc.2021.103395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Polito L, Calafato G, Bortolotti M, Chiarelli Olivari C, Maiello S, Bolognesi A. Antibody Conjugates for Sarcoma Therapy: How Far along Are We? Biomedicines 2021;9:978. [PMID: 34440182 DOI: 10.3390/biomedicines9080978] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Montemagno C, Cassim S, De Leiris N, Durivault J, Faraggi M, Pagès G. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine? Int J Mol Sci 2021;22:6413. [PMID: 34203923 DOI: 10.3390/ijms22126413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]